A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: NK012
Sponsor: Nippon Kayaku Co., Ltd.